Repligen Corporation(RGEN)已同意收购BioLife Solutions Inc.(BLFS),此举旨在通过整合后者市场领先的生物保存介质产品,显著增强其在细胞治疗领域的技术与业务能力。这项交易将Repligen在生物工艺领域的专长与BioLife Solutions在细胞与基因治疗低温保存解决方案方面的领导地位相结合,预计将创造更完整的供应链产品组合,服务于快速增长的先进疗法市场。
Repligen Corporation(RGEN)已同意收购BioLife Solutions Inc.(BLFS),此举旨在通过整合后者市场领先的生物保存介质产品,显著增强其在细胞治疗领域的技术与业务能力。这项交易将Repligen在生物工艺领域的专长与BioLife Solutions在细胞与基因治疗低温保存解决方案方面的领导地位相结合,预计将创造更完整的供应链产品组合,服务于快速增长的先进疗法市场。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.